The 21.1x forward P/E versus 27.1x trailing P/E implies the market is capitalizing approximately 28% earnings growth, which appears reasonable given the accelerating margin trajectory but assumes no reversal in the aerospace build-rate cycle. The 6.44x P/B is notably below Howmet's 14.1x and ATI's 11.6x, yet CRS's ROE of 7.4% substantially trails peers' 25%+ ROE levels, so the book value discount appears partially justified by lower return generation. The 39.0x P/FCF multiple warrants caution, as recent capex intensity has compressed free cash flow, and investors should assess whether the Athens investment cycle is nearing completion before capitalizing forward cash flow recovery.

Operating income grew 81% from $108.3M to $196.4M over the period while SG&A remained virtually flat, confirming exceptional fixed-cost leverage that suggests the operating margin is capturing true incremental earning power rather than accounting distortion. However, the 20.4% net margin in 2027Q1 may be flattered by non-recurring items or working capital timing, and analysts should normalize for the surcharge pass-through effect, which inflates revenue without corresponding profit and structurally depresses reported margin percentages. If the premium mix shift toward LEAP-engine alloys and titanium products continues, there may be additional margin upside, though the 32.1% gross margin should be benchmarked against Howmet's comparable level to assess sustainability.

ROIC has improved from 3.8% to 5.6% over ten quarters, but this remains well below what investors would expect for a business with 24.6% operating margins, indicating the enormous asset base required for VIM and VAR melting capabilities is diluting capital efficiency. The 6.44x P/B valuation implies the market is pricing in future ROIC expansion toward 10%+ as the Athens ramp matures, which would require either further asset rationalization or sustained volume growth to improve the 0.21x asset turnover ratio. Investors should monitor whether ROIC reaches a 7-8% threshold over the next four quarters, as failure to do so may suggest the capital intensity of this business model structurally limits shareholder value creation despite impressive operating margins.

DIO has risen from 115 to 145 days while DPO increased only from 40 to 56 days, indicating inventory is growing faster than the company's ability to offset it with supplier financing — a pattern consistent with pre-building inventory ahead of accelerating aerospace build rates but one that warrants monitoring for destocking risk. DSO has expanded from 62 to 82 days, which may reflect longer payment terms extended to aerospace customers to secure volume commitments, though this also represents working capital leverage being ceded to customers. The 2027Q1 working capital consumption of $166.1M versus the prior quarter's $158.1M release demonstrates the volatility inherent in this cycle lengthening and explains the erratic FCF margin swings from 26.5% to negative 3.1%.

The combination of declining absolute debt ($741.4M to $691.0M) and rapidly expanding EBITDA has produced a D/EBITDA improvement from 5.22x to 2.97x, which provides substantial headroom under most covenant structures and suggests the company could fund a significant acquisition or accelerated buyback without stressing the balance sheet. However, the record $133.9M buyback in 2027Q1 occurred simultaneously with negative FCF of -$24.9M and a 59% sequential decline in cash to $159.5M, a combination that warrants scrutiny of whether management's capital allocation discipline is loosening at an inopportune point in the capex cycle. The 28.1x interest coverage effectively eliminates near-term refinancing risk, but investors should note that coverage ratios for commodity-sensitive businesses can deteriorate rapidly if revenue contracts during an aerospace destocking cycle.